Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 18;24(2):10.
doi: 10.1038/s41397-024-00330-5.

Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study

Vasileios Fragoulakis #  1 , Margarita-Ioanna Koufaki #  2 , Candace Joefield-Roka  3 , Gere Sunder-Plassmann  3 , Christina Mitropoulou  4   5
Affiliations

Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study

Vasileios Fragoulakis et al. Pharmacogenomics J. .

Abstract

Chronic kidney disease (CKD) is a global health issue. Kidney failure patients may undergo a kidney transplantation (KTX) and prescribed an immunosuppressant medication i.e., tacrolimus. Tacrolimus' efficacy and toxicity varies among patients. This study investigates the cost-utility of pharmacogenomics (PGx) guided tacrolimus treatment compared to the conventional approach in Austrian patients undergone KTX, participating in the PREPARE UPGx study. Treatment's effectiveness was determined by mean survival, and utility values were based on a Visual Analog Scale score. Incremental Cost-Effectiveness Ratio was also calculated. PGx-guided treatment arm was found to be cost-effective, resulting in reduced cost (3902 euros less), 6% less hospitalization days and lower risk of adverse drug events compared to the control arm. The PGx-guided arm showed a mean 0.900 QALYs (95% CI: 0.862-0.936) versus 0.851 QALYs (95% CI: 0.814-0.885) in the other arm. In conclusion, PGx-guided tacrolimus treatment represents a cost-saving option in the Austrian healthcare setting.

PubMed Disclaimer

References

    1. Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. NIHR J Libr. 2016;20:1–594.
    1. Mudiayi D, Shojai S, Okpechi I, Christie EA, Wen K, Kamaleldin M, et al. Global estimates of capacity for kidney transplantation in world countries and regions. Transplantation. 2022;106:1113–22. - DOI - PubMed - PMC
    1. Chemello C, Aguilera M, Cañadas Garre M, Calleja MA. Pharmacogenetics and pharmacogenomics of chronic kidney disease comorbidities and kidney transplantation. In: Barh D et al., editors. Omics for personalized medicine. 1st ed. India: Springer eBooks; 2013. p.801–18.
    1. Boenink R, Kramer A, Tuinhout RE, Savoye E, Åsberg A, Idrizi A, et al. Trends in kidney transplantation rate across Europe: study from the ERA Registry. Nephrol Dial Transpl. 2023;38:1528–39. - DOI
    1. McEwan P, Dixon S, Baboolal K, Conway P, Currie CJ. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK. Pharmacoeconomics. 2006;24:67–79. - DOI - PubMed

LinkOut - more resources